PRESS RELEASES

Year
October 18 | 2021
RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit
September 30 | 2021
RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress
September 20 | 2021
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress
September 20 | 2021
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
September 03 | 2021
RAPT Therapeutics to Present at Upcoming Investor Conferences
August 11 | 2021
RAPT Therapeutics Reports Second Quarter 2021 Financial Results
June 18 | 2021
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
June 15 | 2021
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
June 14 | 2021
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
June 14 | 2021
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
June 13 | 2021
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
May 20 | 2021
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 11 | 2021
RAPT Therapeutics Reports First Quarter 2021 Financial Results
March 22 | 2021
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
March 11 | 2021
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results
March 10 | 2021
RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR
March 03 | 2021
RAPT Therapeutics to Participate in Two Investor Conferences in March
February 19 | 2021
RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
January 05 | 2021
RAPT Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference